DENVER--(BUSINESS WIRE)--May 10, 2006--Ceragenix Pharmaceuticals, Inc. today announced that the company has entered into a research agreement with the Johns Hopkins University School of Medicine, under which the Johns Hopkins Burn Center will evaluate the efficacy of Ceragenix’s Ceragenin(TM) Antimicrobial Wound Dressing in animal models of Pseudomonas aeruginosa and methicillin resistant Staphylococcus aureus (MRSA) infections. Pseudomonas aeruginosa is a leading cause of infection and septic mortality in burn patients. MRSA is a multidrug resistant staph infection that has become increasingly prevalent in the past few years.
